The adverse effects of hormone replacement therapy

Drugs and Aging

Volumn 14, Issue 5, 1999, Pages 347-357

  Tavani, Alessandra ^a   La Vecchia, Carlo ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STROKE; VEIN THROMBOSIS;

CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASMS; THROMBOEMBOLISM;

EID: 0032945508     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914050-00003     Document Type: Review

References (99)

1. Brinton LA, Schairer C. Postmenopausal hormone-replacement therapy: Time for a reappraisal? N Engl J Med 1997; 336: 1821-2
2. La Vecchia C. Sex hormones and cardiovascular risk. Hum Reprod 1992; 7: 162-7
3. Fernandez E, La Vecchia C, Braga C, et al. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 329-33
4. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59
6. Willis DB, Calle EE, Miracle-McMahill HL, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449-57
7. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993; 15: 66-79
8. Adami H-O, Persson I. Hormone replacement and breast cancer: A remaining controversy? JAMA 1995; 274: 178-9
9. The Writing Group on the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA, 1996; 275: 370-5
10. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35
11. Stanford JL, Thomas D. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98-107
12. Bergkvist L, Adami H-O, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-7
13. Persson I, Yuen J, Bergkvist L, et al. Combined oestrogen-progestogen replacement and breast cancer risk [letter]. Lancet 1992; 340: 1044
14. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620-35
15. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832-8
16. Persson I, Thurfjell E, Bergstrom R, et al. Hormone replacement therapy and the risk of breast cancer: Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758-61
17. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93
18. Day NE. Epidemiology: The role of multi-stage models. Cancer Surv 1983; 2: 579-93
19. Henderson BE. The cancer question: An overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859-64
20. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-90
21. La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: A cooperative Italian study. Br J Cancer 1995; 72: 244-8
22. Mack TM, Ross RK. Risks and benefits of long-term treatment with estrogens. Schweiz Med Wochenschr 1989; 119: 1811-20
23. Tavani A, Braga C, La Vecchia C, et al. Hormone replacement treatment and breast cancer risk: An age-specific analysis. Cancer Epidemiol Biomarkers Prev 1997; 6: 11-4
24. Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 1995; 173: 982-90
25. Parazzini F, La Vecchia C, Negri E, et al. Determinants of estrogen replacement therapy use in Northern Italy. Rev Epidemiol Sante Publique 1993; 41: 53-8
26. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41: 1-16
27. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975; 293: 1164-7
28. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167-70
29. Schwartzbaum JA, Hulka BS, Fowler Jr WC, et al. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987; 126: 851-60
30. Shapiro S, Kaufman DW, Slone D, et al. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 1980; 303: 485-9
31. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995; 85: 304-13
32. Day NE. Time as a determinant of risk in cancer epidemiology: The role of multi-stage models. Cancer Surv 1983; 2: 577-93
33. Finkle WD, Greenland S, Miettinen OS, et al. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control 1995; 6: 99-102
34. La Vecchia C, Franceschi S, Gallus G, et al. Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol 1982; 11: 120-6
35. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990; 162: 502-14
36. Brinton LA, Hoover RN, for the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993; 81: 265-71
37. Levi F, La Vecchia C, Gulie C, et al. Oestrogen replacement treatment and the risk of endometrial cancer: An assessment of the role of covariates. Eur J Cancer 1993; 29A: 1445-9
38. Pike MC, Age-related factors in cancer of the breast, ovary, and endometrium. J Chronic Dis 1987; 40 Suppl. 2: 59S-69
39. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993; 4: 20-4
40. Parazzini F, Negri E, La Vecchia C, et al. Population attributable risk for endometrial cancer in Northern Italy. Eur J Cancer Clin Oncol 1989; 25: 1451-6
41. Leather AT, Savvas M, Studd JWW. Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1008-10
42. Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274-7
43. Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61
44. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110-6
45. Grady D, Ernster VL. Hormone replacement therapy and endometrial cancer: Are current regimen safe? J Natl Cancer Inst 1997; 89: 1088-9
46. La Vecchia C, Negri E, Levi F, et al. Cancer mortality in Europe: Effects of age, cohort of birth and period of death. Eur J Cancer 1998; 34: 118-41
47. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289-93
48. Rodriguez C, Calle EE, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995; 141: 828-35
49. Adami H-O, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 833-9
50. Schairer C, Adami H-O, Hoover R, et al. Causes-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997; 8: 59-65
51. Hildreth NG, Kelsey JL, LiVolsi VA, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981; 114: 398-405
52. Weiss NS, Lyon JL, Krishnamurthy S, et al. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982; 68: 95-8
53. Franceschi S, La Vecchia C, Helmrich SP, et al. Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol 1982; 115: 714-9
54. Tzonou A, Day NE, Trichopoulos D, et al. The epidemiology of ovarian cancer in Greece: A case-control study. Eur J Cancer Clin Oncol 1984; 20: 1045-52
55. Harlow BL, Weiss, NS, Roth GJ, et al. Case-control study of borderline ovarian tumors: Reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48: 5849-52
56. Kaufman DW, Kelly JP, Welch WR, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989; 130: 1142-51
57. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: A case-control study. Br J Cancer 1989; 60: 592-8
58. Polychronopoulou A, Tzonou A, Hsich C, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993; 55: 402-7
59. Parazzini F, La Vecchia C, Negri E, et al. Estrogen replacement therapy and ovarian cancer risk [letter] Int J Cancer 1994; 57: 135-6
60. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study. Int J Cancer 1995; 62: 678-84
61. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996; 63: 254-7
62. Hempling RE, Wong C, Piver MS, et al. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study. Obstet Gynecol 1997; 89: 1012-6
63. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in White women. Am J Epidemiol 1992; 136: 1184-203
64. Harris R, Whittemore AS, Itnyre J, et al. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epethelial tumors of low malignant potential in White women. Am J Epidemiol 1992; 136: 1204-11
65. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990; 97: 1080-6
66. Garg PP, Kerlikowske K, Suhak L, et al. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A metaanalysis. Obstet Gynecol 1998; 92: 472-9
67. Caine YG, Bauer KA, Barzegar S, et al. Coagulalion activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-5
68. Pfeffer RI. Estrogen use, hypertension and stroke in postmenopausal women. J Chronic Dis 1978; 31: 389-98
69. Petitti DB, Wingerd J, Pellegrin, F, et al. Risk of vascular disease in women: Smoking, oral contraceptives, noncontraceptive estrogens and other factors. JAMA 1979; 242: 1150-4
70. Hammond CB, Jelovsek FR, Lee KL, et al. Effects of long-term estrogen replacement therapy: Metabolic effects. Am J Obstet Gynecol 1979; 133: 525-36
71. Rosenberg SH, Fausone V, Clark R. The role of estrogens as a risk factor for stroke in postmenopausal women. West J Med 1980; 133: 292-6
72. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50: The Framingham study. N Engl J Med 1985; 313: 1038-43
73. Busch TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study. Circulation 1987; 75: 1102-9
74. Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 1988; 19: 1345-53
75. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: A prospective study. BMJ 1988; 297: 519-22
76. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989; 43: 173-8
77. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses Health Study. N Engl J Med 1991; 325: 756-62
78. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37
79. Finneane FF, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort. Arch Intern Med 1993; 153: 73-9
80. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61
81. Falkeborn M, Persson I, Terént A, et al. Hormone replacement therapy and the risk of stroke: Follow-up of a population-based cohort in Sweden. Arch Intern Med 1993; 153: 1201-9
82. Longstreth WT, Nelson LM, Koepsell TD, et al. Subarachnoid hemorrhage and hormonal factors in women: A population-based case-control study. Ann Intern Med 1994; 121: 168-73
83. Pedersen AT, Lidegaard O, Kreiner S, et al. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997; 350: 1277-83
84. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143: 971-8
85. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated oestrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-3
86. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8-15
87. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism and breast tumours in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-9
88. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54, 74-9
89. Petitti DB, Wingerd J, Pelegrin F, et al. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978; 108: 480-5
90. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82
91. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80
92. Jick H, Derby LE, Wald Myers M, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-3
93. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-7
94. Daly E, Vessey MP, Painter R, et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy [letter]. Lancet 1996; 348: 1027
95. Rosenberg L, Palmer JR, Adams-Campbell LL. Postmenopausal female hormone use and venous thromboembolic disease in Black women [letter]. Am J Obstet Gynecol 1997; 177: 1275
96. Pérez Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ 1997; 314: 796-800
97. Varas-Lorenzo C, García-Rodríguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population based study in southern Europe. Am J Epidemiol 1998; 147: 387-90
98. McKenna MJ. Risk of venous thrombosis with hormone replacement therapy [letter]. Lancet 1996; 348: 1668
99. Hulley S, Grady D, Bush T, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13